Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major

Bemani, Effat; Oryan, Ahmad; Bahrami, Somayeh

doi:10.1016/j.exppara.2019.107747

Cited by 9 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Some drugs used for the treatment of arrhythmias in other clinical scenarios, such as amiodarone, have been tested for the treatment of CL in mice, demonstrating a reduction in the parasitic burden and a reduction of the ulcer surface area. 24 Most used medications for this disease can present adverse effects impacting the CV system. Regarding SbV cardiotoxicity, the main manifestation is represented by dose-dependent ECG changes.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Leishmaniasis y corazón

Farina¹,

García-Martínez²,

Saldarriaga³

et al. 2021

ACM

View full text Add to dashboard Cite

As one of the neglected tropical diseases, leishmaniasis is defined as a parasitic communicable disease that is most prevalent in tropical and subtropical regions, affecting especially populations living in poverty. It has a profound negative impact on developing economies. It represents a group of heterogeneous syndromes with a wide spectrum of severity ranging from self-resolving cutaneous injuries to disseminated visceral compromise. Visceral leishmaniasis represents its most severe form, can affect almost all organs, and can have fatal consequences, especially in immunosuppressed patients. Cardiac involvement seems to be rare but has not been deeply studied. Consequently, there are no clear recommendations for the screening of cardiac manifestations in these patients. However, cardiovascular complications could be potentially lethal. In addition, there are valuable reports on the potential cardiotoxicity caused by drugs used in the treatment of this condition, so knowledge of its side effects could have important implications. This article is a part of the "Neglected Tropical Diseases and other Infectious Diseases affecting the Heart" project (the NET-Heart Project); its purpose is to review all the information available regarding cardiac implications of this disease and its treatment and to add knowledge to this field of study, focusing on the barriers for diagnosis and treatment, and how to adopt strategies to overcome them.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Leishmaniasis y corazón

Farina¹,

García-Martínez²,

Saldarriaga³

et al. 2021

ACM

View full text Add to dashboard Cite

show abstract

“…Bemani et al . evaluated amiodarone (S19) (a antiarrhythmic class III drug) against L. major [68] . The authors reported good potential in both in vitro and in vivo analyzes, through tests related to wound healing, immune response, activities of antioxidant enzymes and malondialdehyde (MDA), ferric reducing ability of plasma (FRAP) and adiponectin levels in infected mice.…”

Section: Drug Repurposingmentioning

confidence: 99%

Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre‐Clinical to Clinical Findings

Santana

Oliveira

Ramos

et al. 2021

Chemistry & Biodiversity

View full text Add to dashboard Cite

Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre‐clinical (in vitro, in vivo), drug repurposing and clinical research.

show abstract